Drug Discovery
Selvita is a contract research organisation (CRO) providing drug discovery services from target validation to preclinical candidate nomination, delivered as integrated programmes or standalone, discipline-focused projects.

Selvita operates as a European contract research organization offering drug discovery and preclinical services to pharmaceutical and biotechnology companies.
selvita.comCrawled Nov 17, 2026
Selvita is a contract research organisation (CRO) providing drug discovery services from target validation to preclinical candidate nomination, delivered as integrated programmes or standalone, discipline-focused projects.
Selvita offers antibody-based drug discovery services, including discovery, characterization, developability assessment, and engineering.
GMP and GLP drug development for small molecules, biologics and agrochemicals: CMC, analytics, bioanalysis, formulation, GMP manufacturing, QP release, regulatory
Selvita supports drug discovery for modalities like protein degraders, peptides, macrocycles, ADCs, and CAR-T components with tailored strategies.
Selvita combines chemistry, biology, and AI to provide small molecule drug discovery solutions across disease areas.
Selvita aims to become a leading global contract research and development organization.
The page displays Selvita Group’s financial results and corporate presentations for the last four reporting periods.
Selvita provides career opportunities in drug discovery, development, and scientific or administrative roles.
Selvita’s culture emphasizes passion, excellence, collaboration, and scientific innovation.
Selvita’s chemistry academy offers students hands-on laboratory workshops in organic synthesis.
Selvita’s core values—passion, excellence, commitment, partnerships, and integrity—guide its operations and teamwork.
Selvita offers a paid summer internship program for students to gain practical experience under expert mentorship.
Selvita hosts Open Days to showcase its work in drug discovery and development, highlighting career opportunities and laboratory operations.
The supervisory board oversees the company’s strategic direction and long-term value creation for shareholders.
Anna has 15 years of experience in biotechnology and life sciences, specializing in antibody engineering and design.
Beata Romanowska holds a degree in molecular bioengineering and works as a senior scientist in antibody discovery at Selvita.
Selvita’s leadership team focuses on scientific excellence, innovation, and operational efficiency to foster workplace culture.
Michał Dziurka has over 20 years of experience in analytical chemistry, chromatography, and metabolomics research.
Sonia earned her PhD in chemical biology in 2020, researching peptide synthesis, cell-death studies, and confocal microscopy.
Selvita provides science-driven R&D services for drug discovery, preclinical studies, and GMP/GLP-compliant analytics.
Bylaws of the Management Board of Selvita S.A.
Selvita develops innovative therapies and balances economic value with societal and environmental impact.
Selvita offers flexible research and development services for pharmaceutical and biotech companies.
Selvita’s Supplier Code of Conduct and Terms and Conditions apply to all suppliers, regardless of size or location.
Before sending samples to Selvita, please follow these steps:
Drug discovery, drug development, and contract testing services, bridging the gap between early discovery and clinical development.
Selvita provides integrated solutions supporting clients throughout the drug discovery and development process.
Selvita’s privacy policy explains how it collects, uses, and protects personal data and cookies on its website.
Below, you will find files that you can download and review to read the full Terms and Conditions in English.
Selvita Capital Group has adopted the Whistleblowers policy, laying down rules of conduct in case of Violation of law or of internal ethical rules followed by Selvita.
Selvita updated its **articles of association** on **October 2, 2026**, modifying its **PKD 2025 activity codes** to reflect new classifications. The change follows a recent corporate filing and complements a separate plan to **merge two wholly owned subsidiaries** within the same month. The adjustments align Selvita’s operational scope with updated regulatory frameworks.
Selvita S.A. publishes its Q1 2026 financial results and backlog, showing performance as a leading European drug discovery and development company. The firm initiates a strategic options review to evaluate future growth pathways and enhance long-term shareholder value. The move follows a stated focus on maximizing value amid evolving market conditions.
Selvita is expanding its research capabilities by establishing a new facility in Wroclaw, Poland. The site will feature over 400 square meters of advanced labs equipped for antibody discovery and development. The infrastructure supports Selvita’s growth in biopharmaceutical innovation.
Selvita plans to separate its drug discovery services and oncology R&D into two independent companies by the end of 2019. The Services segment reports a 34% sales growth in 2018 while maintaining profitability. The oncology R&D pipeline continues to advance, though no specific milestones are detailed.
Selvita, Poland’s largest drug discovery company, secures **$5.5 million** in a private placement to advance its pipeline. The funding supports the company’s push to transition compounds into clinical trials, marking a key step toward potential therapeutic development. Selvita specializes in oncology and rare diseases, leveraging its research to identify novel treatment candidates.